[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"attr-amyloidosis-with-cardiomyopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:attr-amyloidosis-with-cardiomyopathy":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100623616",false,"NCT07398950","Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)","Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM): TRACE-AI Prospective Study","TRACE-AI Yale","Inclusion Criteria:\n\n* Patients 18 years or older with at least one of each component cardiovascular diagnosis testing (ECG and Echo) in the YNHHS.\n* Patients with a diagnosis of HFpEF or HFmrEF\n* Participant from Phase I TRACE-AI Study with AI-ECG and AI-Echo screen in the preceding 36 months\n\nExclusion Criteria:\n\n* Patients who have opted out of research studies\n* Patients with cardiac amyloid diagnostic test in the past 36 months\n* Patients with hypertrophic cardiomyopathy or end-stage renal disease\n* Pregnant women\n* Patients unable or unwilling to provide informed consent\n* Non-English speakers and cognitively impaired individuals who are unable to comprehend the consent and the on-screen instructions on the application, which are in English.","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","OBSERVATIONAL","The TRACE-AI Diagnostic Study will evaluate the performance of artificial intelligence (AI) models applied to electrocardiograms (AI-ECG) and echocardiograms (AI-Echo) to identify transthyretin amyloid cardiomyopathy (ATTR-CM) in adults with heart failure. Model performance will be validated through comparison with technetium-99m pyrophosphate (PYP) imaging results.",[24,25],"ATTR Amyloidosis With Cardiomyopathy","Heart Failure",[27,28,29,30,31,32,33,34,35,36],"Transthyretin Amyloid Cardiomyopathy (ATTR-CM)","Artificial Intelligence Screening","AI-ECG","AI-Echo","Electrocardiogram","Technetium-99m Pyrophosphate (Tc99m-PYP) Scintigraphy","Machine Learning in Cardiology","Validation of AI Diagnostic Tools","Cardiomyopathy Screening","Early Detection of Cardiac Amyloidosis","NOT_YET_RECRUITING","2026-02-04",{"date":40,"type":41},"2026-02-10","ACTUAL",{"date":43,"type":20},"2026-03",{"date":45,"type":20},"2026-12",{"name":47,"class":48},"Yale University","OTHER",1,{"id":51,"slug":4,"hasResults":10,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100580339","NCT06836011","A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence, and Prognostic Impact.","Definition and Prognosis of Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy - a Prospective International Multicenter Study","Inclusion Criteria:\n\n* Diagnosis of ATTR-CM according to current diagnostic criteria\n* Comprehensive baseline echocardiographic assessment, including (semi-)quantitative mitral and tricuspid regurgitation (MR\u002FTR) parameters, performed within ±6 months of diagnosis\n* Age ≥ 18 years\n* Willingness to participate in the study and provide informed consent\n\nExclusion Criteria:\n\n* Severe aortic valve disease requiring intervention\n* Inability to provide informed consent or participate in study follow-up",{"count":57,"type":20},600,"The objective of this prospective registry study is to comprehensively characterize the prevalence, (semi-) quantitative parameters, and associated clinical outcomes of mitral (MR) and tricuspid regurgitation (TR) in patients diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM). The study further aims to develop and implement new grading standards for the quantitative assessment of regurgitation severity, tailored to the distinct hemodynamic profile of ATTR-CM. This approach seeks to address the limitations of current regurgitation severity classifications, which do not adequately reflect the unique pathophysiology of a restrictive phenotype as seen in ATTR-CM.",[24,60,61,62,63],"ATTR-CM","ATTR Amyloidosis Wild Type","Mitral Regurgitation","Tricuspid Regurgitation",[60,65,63,62],"ATTR amyloidosis","RECRUITING","2025-02-14",{"date":69,"type":41},"2025-02-19",{"date":71,"type":41},"2025-01-01",{"date":73,"type":20},"2026-12-31",{"name":75,"class":48},"Medical University of Vienna",8,""]